Hoffmann-La Roche posts results of Phase III obinutuzumab study in systemic lupus erythematosus
Results for the study were first posted on ClinicalTrials.gov on November 12, 2026. The Phase III trial enrolled 303 participants, with primary completion on September 15, 2025, and compared obinutuzumab to placebo in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard-of-care therapy.
Primary source
ClinicalTrials.gov results record, November 12, 2026
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
Read the source: A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation